肺炎药物市场规模、份额和增长分析（按产品、药物类别、给药途径、感染方式、年龄组和地区）- 行业预测 2025-2032

2023 年肺炎药物市场规模价值 112.9 亿美元，预计将从 2024 年的 122.4 亿美元成长到 2032 年的 233.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.4%。

全球肺炎药物市场正在成长，这得益于肺炎盛行率的不断上升，尤其是在老年人和免疫力缺乏中。社区型肺炎仍然是一个值得关注的问题，人们越来越意识到早期诊断和治疗的重要性。这一背景促进了诊断技术和评估工具的进步，也加强了医疗保健提供者的治疗指南。市场开发提供广泛的抗生素、抗病毒药物和支持性治疗，同时注重个人化医疗以开发标靶治疗。然而，抗生素抗药性和医疗保健机会不平等等挑战仍然存在。总体而言，持续的医学进步和人口变化表明未来几年肺炎治疗市场将呈现良好的发展轨迹。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局
• 专利分析

肺炎治疗药物市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 药物
• 疫苗
• 氧气疗法

肺炎治疗市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概况
• 抗生素
• 抗病毒药物
• 抗真菌药物

肺炎治疗药物市场规模（依给药途径及复合年增长率） (2025-2032)

• 市场概况
• 口服
• 肠外
• 吸入

肺炎治疗药物市场规模（按感染类型和复合年增长率） (2025-2032)

• 市场概况
• 院内获得性肺炎（HAP）
• 社区型肺炎 (CAP)
• 人工呼吸器相关性肺炎 (VAP)

肺炎治疗药物市场规模（依年龄层划分）及复合年增长率（2025-2032）

• 市场概况
• 孩子们
• 成人
• 老年人

肺炎治疗药物市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 网路药局

肺炎治疗药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• GlaxoSmithKline plc（UK）
• AstraZeneca（UK）
• Novartis AG（Switzerland）
• Sanofi（France）
• Bayer AG（Germany）
• Eli Lilly and Company（USA）
• Abbott Laboratories（USA）
• Cipla Inc.（India）
• Lupin Pharmaceuticals Ltd.（India）
• Nabriva Therapeutics AG（Austria）
• Biotest AG（Germany）
• SetLance SRL（Italy）
• Biogen（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Johnson & Johnson（USA）
• Gilead Sciences, Inc.（USA）

结论和建议

Pneumonia Therapeutics Market size was valued at USD 11.29 billion in 2023 and is poised to grow from USD 12.24 billion in 2024 to USD 23.33 billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).

The global pneumonia therapeutics market is experiencing growth driven by the rising pneumonia prevalence, particularly among the elderly and immunocompromised. Community-acquired pneumonia remains a notable concern, with increasing awareness surrounding the significance of early diagnosis and treatment. This impetus has spurred advancements in diagnostic techniques and assessment tools, enhancing treatment guidelines for healthcare providers. The market offers a diverse range of antibiotics, antiviral medications, and supportive therapies, alongside a focus on personalized medicine to develop targeted treatments. However, challenges such as antibiotic resistance and healthcare access disparities persist. Overall, ongoing medical advancements and demographic shifts indicate a promising trajectory for the pneumonia therapeutics market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pneumonia Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pneumonia Therapeutics Market Segments Analysis

Global Pneumonia Therapeutics Market is segmented by Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel and region. Based on Product, the market is segmented into Drugs, Vaccines and Oxygen Therapy. Based on Drug Class, the market is segmented into Antibacterial Drugs, Antiviral Drugs and Antifungal Drugs. Based on Route of Administration, the market is segmented into Oral, Parenteral and Inhalation. Based on Mode of Infection, the market is segmented into Hospital-acquired Pneumonia (HAP), Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP). Based on Age Group, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pneumonia Therapeutics Market

The pneumonia therapeutics market is primarily fueled by the widespread prevalence of pneumonia, which poses a serious health threat, especially among at-risk groups including the elderly, infants, and those with weakened immune systems. As the incidence of pneumonia continues to increase globally, there is an urgent need for effective treatment options to combat this illness. This growing demand for innovative and efficient therapeutic solutions contributes significantly to the expansion of the pneumonia therapeutics market. Addressing the healthcare needs of vulnerable populations highlights the necessity for advancements in pneumonia treatment, ultimately driving market growth in this crucial sector.

Restraints in the Pneumonia Therapeutics Market

A significant limitation within the Pneumonia Therapeutics market is the issue of antibiotic resistance. The overuse and improper use of antibiotics have led to the development of drug-resistant bacterial strains, which pose a considerable challenge in effectively treating pneumonia. This growing resistance diminishes the effectiveness of existing treatment options and highlights an urgent need for innovative and alternative therapeutic approaches. As conventional antibiotics become less viable, healthcare providers and researchers are compelled to explore new strategies to combat pneumonia, underscoring the importance of addressing this restraint in the ongoing development of pneumonia treatments.

Market Trends of the Pneumonia Therapeutics Market

The pneumonia therapeutics market is witnessing a significant trend driven by an increased focus on drug development and research to address the challenges posed by drug-resistant bacterial strains. Pharmaceutical companies are channeling substantial investments into creating innovative antibiotics and alternative therapeutic strategies to enhance treatment efficacy. This momentum is underscored by the urgent need to combat the rising prevalence of antibiotic-resistant infections, which poses a serious public health threat. As a result, the landscape of pneumonia therapeutics is evolving, with stakeholders prioritizing advanced research initiatives that promise to redefine treatment paradigms and improve patient outcomes in the face of growing microbial resistance.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Pneumonia Therapeutics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Drugs
• Vaccines
• Oxygen Therapy

Global Pneumonia Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

Global Pneumonia Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Inhalation

Global Pneumonia Therapeutics Market Size by Mode of Infection & CAGR (2025-2032)

• Market Overview
• Hospital-acquired Pneumonia (HAP)
• Community-acquired Pneumonia (CAP)
• Ventilator-associated Pneumonia (VAP)

Global Pneumonia Therapeutics Market Size by Age Group & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Pneumonia Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Pneumonia Therapeutics Market Size & CAGR (2025-2032)

• North America (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • US
  • Canada
• Europe (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SetLance SRL (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations